How does RYTM's earnings trend compare to industry peers?

Rhythm Pharmaceuticals (RYTM) has a negative net income of $43.29 million, while its peers, Eli Lilly (LLY), Merck (MRK), and Pfizer (PFE), have significantly higher net incomes of $4.41 billion, $3.75 billion, and $418 million, respectively. This indicates that RYTM's earnings trend is significantly weaker than that of its industry peers.

|code|Ticker|Name|Date|Total Revenue|Net Income|Diluted EPS|market_code|
|---|---|---|---|---|---|---|---|
|MRK|MRK.N|Merck|2024 Q1|1.5775E10|4.767E9|1.87|169|
|RYTM|RYTM.O|Rhythm|2024 Q1|2.5967E7|-1.41372E8|-2.35|185|
|PFE|PFE.N|Pfizer|2024 Q1|1.4879E10|3.123E9|0.55|169|
|LLY|LLY.N|Eli Lilly|2024 Q1|8.768E9|2.2429E9|2.48|169|
|MRK|MRK.N|Merck|2024 Q2|1.6112E10|5.461E9|2.14|169|
|RYTM|RYTM.O|Rhythm|2024 Q2|2.9078E7|-3.2261E7|-0.55|185|
|PFE|PFE.N|Pfizer|2024 Q2|1.3283E10|4.8E7|0.01|169|
|LLY|LLY.N|Eli Lilly|2024 Q2|1.13028E10|2.967E9|3.28|169|
|MRK|MRK.N|Merck|2024 Q3|1.6657E10|3.161E9|1.24|169|
|RYTM|RYTM.O|Rhythm|2024 Q3|3.3251E7|-4.3641E7|-0.73|185|